CytoVas, a diagnostics company in University of Pennsylvania’s UPStart incubator program in its Center for Technology Transfer has forged an alliance with a division of diagnostic company Becton Dickinson (NYSE: BDX) to advance a blood-based diagnostic to determine personal risk of cardiovascular disease and stroke.
The alliance with Becton Bioscience will help CytoVas assess cardiovascular disease progression, as well as evaluate the side effects of existing and experimental medicines for cardiovascular disease.
To read the original article: Becton Dickinson forms alliance with Penn incubator company CytoVas | MedCity News
